首页 > 最新文献

Blood Research最新文献

英文 中文
Effects of immune system cells in GvHD and corresponding therapeutic strategies. 免疫系统细胞在GvHD中的作用及其治疗策略。
IF 2.2 Q2 HEMATOLOGY Pub Date : 2023-03-31 DOI: 10.5045/br.2023.2022192
Maryam Jadid Tavaf, Mahboobeh Ebrahimi Verkiani, Fateme Poorhoseini Hanzaii, Mina Soufi Zomorrod

Allogeneic tissue transplantation is one of the most effective treatments for several diseases and injuries, in particular, malignant and non-malignant hematological conditions. Following this procedure, transplanted tissue encounters various complications, one of the most serious being graft-versus-host disease (GvHD). The management of GvHD directly affects the success of transplantation and the survival rate of the patient; therefore, many studies have focused on GvHD prevention and control. This review briefly explains the transplantation process, causes of graft rejection, and importance of the human leukocyte antigen system. Initially, we address the pathophysiology and immunobiology of GvHD, the cells involved in this complication, the differences between chronic and acute GvHD, and the importance of graft-versus-leukemia. Interestingly, various types of immune cells are involved in GvHD pathogenesis. After explaining how these cells affect the GvHD process, we discuss the studies conducted to control and reduce GvHD symptoms.

同种异体组织移植是治疗多种疾病和损伤,特别是恶性和非恶性血液病最有效的方法之一。在此过程中,移植组织会遇到各种并发症,其中最严重的是移植物抗宿主病(GvHD)。GvHD的处理直接影响移植的成功和患者的生存率;因此,GvHD的预防和控制成为许多研究的重点。本文简要介绍了移植过程、移植排斥反应的原因以及人白细胞抗原系统的重要性。首先,我们讨论了GvHD的病理生理学和免疫生物学,参与这种并发症的细胞,慢性和急性GvHD之间的差异,以及移植物抗白血病的重要性。有趣的是,多种类型的免疫细胞参与了GvHD的发病机制。在解释了这些细胞如何影响GvHD过程之后,我们讨论了控制和减少GvHD症状的研究。
{"title":"Effects of immune system cells in GvHD and corresponding therapeutic strategies.","authors":"Maryam Jadid Tavaf,&nbsp;Mahboobeh Ebrahimi Verkiani,&nbsp;Fateme Poorhoseini Hanzaii,&nbsp;Mina Soufi Zomorrod","doi":"10.5045/br.2023.2022192","DOIUrl":"https://doi.org/10.5045/br.2023.2022192","url":null,"abstract":"<p><p>Allogeneic tissue transplantation is one of the most effective treatments for several diseases and injuries, in particular, malignant and non-malignant hematological conditions. Following this procedure, transplanted tissue encounters various complications, one of the most serious being graft-versus-host disease (GvHD). The management of GvHD directly affects the success of transplantation and the survival rate of the patient; therefore, many studies have focused on GvHD prevention and control. This review briefly explains the transplantation process, causes of graft rejection, and importance of the human leukocyte antigen system. Initially, we address the pathophysiology and immunobiology of GvHD, the cells involved in this complication, the differences between chronic and acute GvHD, and the importance of graft-versus-leukemia. Interestingly, various types of immune cells are involved in GvHD pathogenesis. After explaining how these cells affect the GvHD process, we discuss the studies conducted to control and reduce GvHD symptoms.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 1","pages":"2-12"},"PeriodicalIF":2.2,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/11/1f/br-58-1-2.PMC10063589.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9581903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
High rate of hepatitis B reactivation during tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia in Korea. 韩国慢性髓性白血病患者酪氨酸激酶抑制剂治疗期间乙型肝炎再激活率高。
IF 2.2 Q2 HEMATOLOGY Pub Date : 2022-12-31 DOI: 10.5045/br.2022.2022099
Jee Hyun Kong, Jae Yeon Jang, Tae Hwa Ko, Seong Hee Kang, Yundeok Kim
Median age (yr) 52 (20–91) Sex male (N, %) 1,386 (60.8) Median duration of TKI treatment, months (range) 51.3 (1–160.5) TKI Imatinib, N (%) 1,563 (68.6) Dasatinib, N (%) 825 (36.2) Nilotinib, N (%) 678 (29.8) Radotinib, N (%) 154 (6.8) N of TKIs 1 TKI, N (%) 1,552 (68.1) 2 TKIs, N (%) 533 (23.4) 3 TKIs, N(%) 171 (7.5) 4 TKIs, N (%) 22 (1.0) HBV infection, N (%) 143 (6.3) HBV reactivation, N (% of HBV carrier) 33 (23.1) During imatinib, N 24 During dasatinib, N 6 During nilotinib, N 1 During radotinib, N 0 HBV reactivation events/1,000 patients-year Imatinib, events/1,000 patients-year 3.5 Dasatinib, events/1,000 patients-year 3.0 Nilotinib, events/1,000 patients-year 0.6 Radotinib, events/1,000 patients-year 0 Median interval (mo) from TKI initiation to HBV reactivation, (range) 2 (0–67) Death, N (%) 466 (20.5)
{"title":"High rate of hepatitis B reactivation during tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia in Korea.","authors":"Jee Hyun Kong,&nbsp;Jae Yeon Jang,&nbsp;Tae Hwa Ko,&nbsp;Seong Hee Kang,&nbsp;Yundeok Kim","doi":"10.5045/br.2022.2022099","DOIUrl":"https://doi.org/10.5045/br.2022.2022099","url":null,"abstract":"Median age (yr) 52 (20–91) Sex male (N, %) 1,386 (60.8) Median duration of TKI treatment, months (range) 51.3 (1–160.5) TKI Imatinib, N (%) 1,563 (68.6) Dasatinib, N (%) 825 (36.2) Nilotinib, N (%) 678 (29.8) Radotinib, N (%) 154 (6.8) N of TKIs 1 TKI, N (%) 1,552 (68.1) 2 TKIs, N (%) 533 (23.4) 3 TKIs, N(%) 171 (7.5) 4 TKIs, N (%) 22 (1.0) HBV infection, N (%) 143 (6.3) HBV reactivation, N (% of HBV carrier) 33 (23.1) During imatinib, N 24 During dasatinib, N 6 During nilotinib, N 1 During radotinib, N 0 HBV reactivation events/1,000 patients-year Imatinib, events/1,000 patients-year 3.5 Dasatinib, events/1,000 patients-year 3.0 Nilotinib, events/1,000 patients-year 0.6 Radotinib, events/1,000 patients-year 0 Median interval (mo) from TKI initiation to HBV reactivation, (range) 2 (0–67) Death, N (%) 466 (20.5)","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"57 4","pages":"290-293"},"PeriodicalIF":2.2,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/05/7e/br-57-4-290.PMC9812728.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10364761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Various inclusions in chronic lymphocytic leukemia/small lymphocytic lymphoma. 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的各种包涵体。
IF 2.2 Q2 HEMATOLOGY Pub Date : 2022-12-31 DOI: 10.5045/br.2022.2022120
Verónica Roldán Galiacho, Ana Lobo Olmedo, Javier Arzuaga Mendez, Juan Carlos García-Ruiz
(A) Globular inclusions in peripheral blood lymphocytes in a 67-year-old woman with 5-year history of CLL managed with a “watch and wait” approach. Other findings included increased lymphocyte count of 270×10 9 /L, hemoglobin of 110 g/L, and platelets of 78×10 9 /L. Serum lactate dehydrogenase level was normal. Positron emission tomography/ computed tomography revealed multiple adenopathies with low SUV and no evidence of transformation. (B) Multiple crystalline inclusions in peripheral blood lymphocytes in a 60-year-old asymptomatic woman with axillary lymphadenopathies. Laboratory evaluations revealed the following: hemoglobin of 132 g/L, platelets of 212×10 9 /L, and lymphocytes of 3.7×10 9 /L. B-cells revealed clonal CLL phenotype on flow cytometry. Lymph node biopsy revealed lymphoid infiltrate with low Ki67 and positivity for CD20, CD23, and CD5. A diagnosis of SLL was established
{"title":"Various inclusions in chronic lymphocytic leukemia/small lymphocytic lymphoma.","authors":"Verónica Roldán Galiacho,&nbsp;Ana Lobo Olmedo,&nbsp;Javier Arzuaga Mendez,&nbsp;Juan Carlos García-Ruiz","doi":"10.5045/br.2022.2022120","DOIUrl":"https://doi.org/10.5045/br.2022.2022120","url":null,"abstract":"(A) Globular inclusions in peripheral blood lymphocytes in a 67-year-old woman with 5-year history of CLL managed with a “watch and wait” approach. Other findings included increased lymphocyte count of 270×10 9 /L, hemoglobin of 110 g/L, and platelets of 78×10 9 /L. Serum lactate dehydrogenase level was normal. Positron emission tomography/ computed tomography revealed multiple adenopathies with low SUV and no evidence of transformation. (B) Multiple crystalline inclusions in peripheral blood lymphocytes in a 60-year-old asymptomatic woman with axillary lymphadenopathies. Laboratory evaluations revealed the following: hemoglobin of 132 g/L, platelets of 212×10 9 /L, and lymphocytes of 3.7×10 9 /L. B-cells revealed clonal CLL phenotype on flow cytometry. Lymph node biopsy revealed lymphoid infiltrate with low Ki67 and positivity for CD20, CD23, and CD5. A diagnosis of SLL was established","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"57 4","pages":"247"},"PeriodicalIF":2.2,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/04/br-57-4-247.PMC9812721.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10589508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum. 勘误表。
IF 2.2 Q2 HEMATOLOGY Pub Date : 2022-12-31 DOI: 10.5045/br.2022.2022089e1
{"title":"Erratum.","authors":"","doi":"10.5045/br.2022.2022089e1","DOIUrl":"https://doi.org/10.5045/br.2022.2022089e1","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"57 4","pages":"297"},"PeriodicalIF":2.2,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/c6/br-57-4-297.PMC9812730.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10643566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Red blood cells from COVID-19 patients suffer from increased oxidative stress and may have increased lactate influx. COVID-19患者的红细胞氧化应激增加,可能会增加乳酸流入。
IF 2.2 Q2 HEMATOLOGY Pub Date : 2022-12-31 DOI: 10.5045/br.2022.2022084
Edel Mullen, Stephen Bergin, Geraldine Healy, John Quinn, Siobhan Glavey, Philip Thomas Murphy
TO THE EDITOR: Coronavirus disease (COVID-19) is caused by SARS-CoV-2, a novel, highly infectious, single stranded RNA virus. An inappropriate immune response characterised by the excess production of pro-inflammatory cytokines (‘cytokine storm’) is common in severe cases of COVID-19 [1]. Such severe disease is frequently complicated by coagulopathy, often progressing to DIC and multi-organ failure [2]. The ‘cytokine storm’ accompanying severe COVID-19 as well as increased serum ferritin levels may be important sources of endogenous oxidative stress [3, 4] Such excess oxidative stress may lead to tissue damage in the lungs and elsewhere by generation of reactive oxygen species (ROS) [5]. The potential role of red blood cells (RBCs) in the pathophysiology of COVID-19, especially their possible contribution to hypoxia and to the thrombotic complications remains uncertain. Both anemia and increase in RBC distribution width have now been associated with increased mortality in hospitalized patients with SARS-CoV-2 infection [6, 7]. In addition, increased oxidation of structural proteins and impairment of membrane lipid homeostasis is reported in RBCs of COVID-19 positive patients, which may alter RBC deformability, potentially contributing to the thromboembolic complications seen in severe forms of COVID-19 infection [8]. To further investigate the possible role of RBC dysfunction in COVID-19, we measured ROS in RBCs of patients infected with COVID-19 at our hospital and the effect of the anti-oxidant N-acetyl cysteine (NAC). To look for evidence of increased adherence of RBCs to endothelial cells (ECs) and platelets in COVID-19 which might contribute to thrombosis, we measured RBC surface expression of adhesion molecules CD44, CD242 (ICAM-4) and CD47, as these red blood cell surface proteins have been implicated in interactions with blood vessels and/or platelets [9]. We also measured surface expression of CD147, as a surrogate marker of the lactate transporter monocarboxylate transporter 1 (MCT1) [10].
{"title":"Red blood cells from COVID-19 patients suffer from increased oxidative stress and may have increased lactate influx.","authors":"Edel Mullen,&nbsp;Stephen Bergin,&nbsp;Geraldine Healy,&nbsp;John Quinn,&nbsp;Siobhan Glavey,&nbsp;Philip Thomas Murphy","doi":"10.5045/br.2022.2022084","DOIUrl":"https://doi.org/10.5045/br.2022.2022084","url":null,"abstract":"TO THE EDITOR: Coronavirus disease (COVID-19) is caused by SARS-CoV-2, a novel, highly infectious, single stranded RNA virus. An inappropriate immune response characterised by the excess production of pro-inflammatory cytokines (‘cytokine storm’) is common in severe cases of COVID-19 [1]. Such severe disease is frequently complicated by coagulopathy, often progressing to DIC and multi-organ failure [2]. The ‘cytokine storm’ accompanying severe COVID-19 as well as increased serum ferritin levels may be important sources of endogenous oxidative stress [3, 4] Such excess oxidative stress may lead to tissue damage in the lungs and elsewhere by generation of reactive oxygen species (ROS) [5]. The potential role of red blood cells (RBCs) in the pathophysiology of COVID-19, especially their possible contribution to hypoxia and to the thrombotic complications remains uncertain. Both anemia and increase in RBC distribution width have now been associated with increased mortality in hospitalized patients with SARS-CoV-2 infection [6, 7]. In addition, increased oxidation of structural proteins and impairment of membrane lipid homeostasis is reported in RBCs of COVID-19 positive patients, which may alter RBC deformability, potentially contributing to the thromboembolic complications seen in severe forms of COVID-19 infection [8]. To further investigate the possible role of RBC dysfunction in COVID-19, we measured ROS in RBCs of patients infected with COVID-19 at our hospital and the effect of the anti-oxidant N-acetyl cysteine (NAC). To look for evidence of increased adherence of RBCs to endothelial cells (ECs) and platelets in COVID-19 which might contribute to thrombosis, we measured RBC surface expression of adhesion molecules CD44, CD242 (ICAM-4) and CD47, as these red blood cell surface proteins have been implicated in interactions with blood vessels and/or platelets [9]. We also measured surface expression of CD147, as a surrogate marker of the lactate transporter monocarboxylate transporter 1 (MCT1) [10].","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"57 4","pages":"294-296"},"PeriodicalIF":2.2,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/29/br-57-4-294.PMC9812725.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10643568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group. 印度尼西亚血友病A患儿FVIII抑制剂监测:印度尼西亚儿童血液肿瘤学工作组的一份报告
IF 2.2 Q2 HEMATOLOGY Pub Date : 2022-12-31 DOI: 10.5045/br.2022.2022153
Novie A Chozie, Djajadiman Gatot, Bambang Sudarmanto, Susi Susanah, Rini Purnamasari, Pudjo Hagung Widjajanto, Susanto Nugroho, Olga Rasiyanti, Dian Puspitasari, Muhammad Riza, Maria C Shanty Larasati, Sri Suryo Adiyanti, Made Citra Saraswati, Fitri Primacakti

Background: Factor VIII (FVIII) inhibitor diagnosis and surveillance in Indonesia are challenging owing to geographic conditions and the lack of laboratory facilities nationwide for inhibitor assays. This study aimed to determine the prevalence of FVIII inhibitors in children diagnosed with hemophilia A (HA) in Indonesia.

Methods: A cross-sectional study was conducted in 12 hospitals in eight provinces of Indonesia between 2020 and 2021. Factor VIII inhibitor screening was performed in a central hemostasis laboratory for all children with HA (≤18 yr) who had received a minimum of 10 exposure days to clotting factor concentrates. The FVIII inhibitor titer was determined using the Bethesda assay.

Results: Children (388) were enrolled in this study, including 219 (56.4%), 131 (33.8%), and 38 (9.4%) with severe, moderate, and mild HA, respectively. The prevalence of children who developed FVIII inhibitors was 37 out of 388 (9.6%). Factor VIII inhibitors were found in 25/219 (11.4%) severe, 11/131 (8.3%) moderate, and 1/38 (2.6%) children with mild HA. Thirteen children had low-titer inhibitors and 24 had high-titer inhibitors, with a median of 9.44 (1.48‒412.0) Bethesda Units. Among 13 children with low-titer inhibitors, eight underwent a confirmation test, of which five tested negative and were classified as transient. A significant difference in annual joint bleeding rate was found between patients with low and high inhibitor titers and those without inhibitors (P<0.001).

Conclusion: Factor VIII inhibitor prevalence in Indonesia was relatively low. However, the risk factors that may contribute to FVIII inhibitor development among Indonesian patients require further study.

背景:由于地理条件和全国缺乏用于抑制剂测定的实验室设施,印度尼西亚的因子VIII (FVIII)抑制剂诊断和监测具有挑战性。本研究旨在确定FVIII抑制剂在印度尼西亚诊断为血友病A (HA)的儿童中的患病率。方法:在2020年至2021年期间在印度尼西亚8个省的12家医院进行横断面研究。在中心止血实验室对所有接受凝血因子浓缩物至少10天暴露的HA患儿(≤18岁)进行因子VIII抑制剂筛选。采用Bethesda法测定FVIII抑制剂滴度。结果:388例儿童入组,其中重度、中度和轻度HA分别为219例(56.4%)、131例(33.8%)和38例(9.4%)。发生FVIII抑制剂的儿童患病率为388例中的37例(9.6%)。在25/219(11.4%)重度、11/131(8.3%)中度和1/38(2.6%)轻度HA患儿中发现因子VIII抑制剂。13名儿童患有低效价抑制剂,24名患有高效价抑制剂,中位数为9.44(1.48-412.0)贝塞斯达单位。在13名患有低效价抑制剂的儿童中,8名接受了确认试验,其中5名检测为阴性,并被归类为短暂性。低、高抑制剂滴度患者和无抑制剂患者的年关节出血率有显著差异(P<0.001)。结论:因子VIII抑制剂在印尼的患病率相对较低。然而,印尼患者中可能导致FVIII抑制剂发展的危险因素需要进一步研究。
{"title":"FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group.","authors":"Novie A Chozie,&nbsp;Djajadiman Gatot,&nbsp;Bambang Sudarmanto,&nbsp;Susi Susanah,&nbsp;Rini Purnamasari,&nbsp;Pudjo Hagung Widjajanto,&nbsp;Susanto Nugroho,&nbsp;Olga Rasiyanti,&nbsp;Dian Puspitasari,&nbsp;Muhammad Riza,&nbsp;Maria C Shanty Larasati,&nbsp;Sri Suryo Adiyanti,&nbsp;Made Citra Saraswati,&nbsp;Fitri Primacakti","doi":"10.5045/br.2022.2022153","DOIUrl":"https://doi.org/10.5045/br.2022.2022153","url":null,"abstract":"<p><strong>Background: </strong>Factor VIII (FVIII) inhibitor diagnosis and surveillance in Indonesia are challenging owing to geographic conditions and the lack of laboratory facilities nationwide for inhibitor assays. This study aimed to determine the prevalence of FVIII inhibitors in children diagnosed with hemophilia A (HA) in Indonesia.</p><p><strong>Methods: </strong>A cross-sectional study was conducted in 12 hospitals in eight provinces of Indonesia between 2020 and 2021. Factor VIII inhibitor screening was performed in a central hemostasis laboratory for all children with HA (≤18 yr) who had received a minimum of 10 exposure days to clotting factor concentrates. The FVIII inhibitor titer was determined using the Bethesda assay.</p><p><strong>Results: </strong>Children (388) were enrolled in this study, including 219 (56.4%), 131 (33.8%), and 38 (9.4%) with severe, moderate, and mild HA, respectively. The prevalence of children who developed FVIII inhibitors was 37 out of 388 (9.6%). Factor VIII inhibitors were found in 25/219 (11.4%) severe, 11/131 (8.3%) moderate, and 1/38 (2.6%) children with mild HA. Thirteen children had low-titer inhibitors and 24 had high-titer inhibitors, with a median of 9.44 (1.48‒412.0) Bethesda Units. Among 13 children with low-titer inhibitors, eight underwent a confirmation test, of which five tested negative and were classified as transient. A significant difference in annual joint bleeding rate was found between patients with low and high inhibitor titers and those without inhibitors (<i>P</i><0.001).</p><p><strong>Conclusion: </strong>Factor VIII inhibitor prevalence in Indonesia was relatively low. However, the risk factors that may contribute to FVIII inhibitor development among Indonesian patients require further study.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"57 4","pages":"272-277"},"PeriodicalIF":2.2,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/97/br-57-4-272.PMC9812731.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9204823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic impact of total body irradiation dose in pediatric acute lymphoblastic leukemia patients treated with allogeneic hematopoietic stem cell transplantation in second complete remission. 全身照射剂量对小儿急性淋巴细胞白血病异基因造血干细胞移植第二次完全缓解患者预后的影响。
IF 2.2 Q2 HEMATOLOGY Pub Date : 2022-12-31 DOI: 10.5045/br.2022.2022174
Wonjin Jang, Suejung Jo, Jae Won Yoo, Seongkoo Kim, Jae Wook Lee, Pil-Sang Jang, Nack-Gyun Chung, Bin Cho

Background: Allogeneic HSCT may improve survival in pediatric ALL patients who relapse. In this study, we analyzed the outcome and prognostic factors of 62 ALL patients (35 male, 56.5%) who received allogeneic HSCT in second complete remission (CR) at our institution between April 1st 2009 and December 31st 2019.

Methods: The median time from diagnosis to relapse was 35.1 months (range, 6.0‒113.6 mo). Fifty-three patients (85.5%) experienced bone marrow relapse only. The number of patients who received transplant according to each donor type was as follows: HLA matched family donor 17 (27.4%), matched unrelated donor (UD) 22 (35.5%), mismatched donor 23 (37.1%). All patients received HSCT with a myeloablative conditioning, 58 patients (93.5%) with the incorporation of TBI [31 patients 12 Gray (Gy), 24 patients 13.2 Gy, 3 patients 8 Gy].

Results: The 5-year event-free survival (EFS), and overall survival of the study group was 41.3±6.3% (26/62), and 42.3±6.6% (27/62), respectively. The cumulative incidence of relapse and transplant-related mortality was 57.1±6.4% and 1.6±1.6%, respectively. Infant ALL, shorter time from diagnosis to relapse, and TBI dose of 12 Gy, rather than 13.2 Gy, resulted in significantly worse EFS. In multivariate analysis, infant ALL and TBI dose of 12 Gy during conditioning predicted significantly lower EFS.

Conclusion: In our study group, treatment with a higher dose of TBI during conditioning resulted in better EFS for ALL patients who underwent HSCT in second CR. Further study is needed to determine potential long-term complications associated with a higher TBI dose.

背景:同种异体造血干细胞移植可能提高复发的儿科ALL患者的生存率。在这项研究中,我们分析了2009年4月1日至2019年12月31日在我们机构接受第二次完全缓解(CR)的62例ALL患者(35例男性,56.5%)的结局和预后因素。方法:从诊断到复发的中位时间为35.1个月(范围:6.0-113.6个月)。53例(85.5%)仅发生骨髓复发。按供体类型进行移植的患者数为:HLA匹配家族供体17例(27.4%),匹配非亲属供体22例(35.5%),错配供体23例(37.1%)。所有患者均接受骨髓清除条件下的HSCT, 58例(93.5%)合并TBI[31例12 Gy, 24例13.2 Gy, 3例8 Gy]。结果:研究组的5年无事件生存率(EFS)和总生存率分别为41.3±6.3%(26/62)和42.3±6.6%(27/62)。累计复发率和移植相关死亡率分别为57.1±6.4%和1.6±1.6%。婴儿ALL,从诊断到复发的时间较短,TBI剂量为12 Gy而不是13.2 Gy,导致EFS明显恶化。在多变量分析中,调节期间婴儿ALL和TBI剂量为12 Gy预测显著降低的EFS。结论:在我们的研究组中,在第二次CR中接受HSCT的ALL患者,在适应症期间接受更高剂量的TBI治疗可以获得更好的EFS,需要进一步的研究来确定高剂量TBI相关的潜在长期并发症。
{"title":"Prognostic impact of total body irradiation dose in pediatric acute lymphoblastic leukemia patients treated with allogeneic hematopoietic stem cell transplantation in second complete remission.","authors":"Wonjin Jang,&nbsp;Suejung Jo,&nbsp;Jae Won Yoo,&nbsp;Seongkoo Kim,&nbsp;Jae Wook Lee,&nbsp;Pil-Sang Jang,&nbsp;Nack-Gyun Chung,&nbsp;Bin Cho","doi":"10.5045/br.2022.2022174","DOIUrl":"https://doi.org/10.5045/br.2022.2022174","url":null,"abstract":"<p><strong>Background: </strong>Allogeneic HSCT may improve survival in pediatric ALL patients who relapse. In this study, we analyzed the outcome and prognostic factors of 62 ALL patients (35 male, 56.5%) who received allogeneic HSCT in second complete remission (CR) at our institution between April 1st 2009 and December 31st 2019.</p><p><strong>Methods: </strong>The median time from diagnosis to relapse was 35.1 months (range, 6.0‒113.6 mo). Fifty-three patients (85.5%) experienced bone marrow relapse only. The number of patients who received transplant according to each donor type was as follows: HLA matched family donor 17 (27.4%), matched unrelated donor (UD) 22 (35.5%), mismatched donor 23 (37.1%). All patients received HSCT with a myeloablative conditioning, 58 patients (93.5%) with the incorporation of TBI [31 patients 12 Gray (Gy), 24 patients 13.2 Gy, 3 patients 8 Gy].</p><p><strong>Results: </strong>The 5-year event-free survival (EFS), and overall survival of the study group was 41.3±6.3% (26/62), and 42.3±6.6% (27/62), respectively. The cumulative incidence of relapse and transplant-related mortality was 57.1±6.4% and 1.6±1.6%, respectively. Infant ALL, shorter time from diagnosis to relapse, and TBI dose of 12 Gy, rather than 13.2 Gy, resulted in significantly worse EFS. In multivariate analysis, infant ALL and TBI dose of 12 Gy during conditioning predicted significantly lower EFS.</p><p><strong>Conclusion: </strong>In our study group, treatment with a higher dose of TBI during conditioning resulted in better EFS for ALL patients who underwent HSCT in second CR. Further study is needed to determine potential long-term complications associated with a higher TBI dose.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"57 4","pages":"256-263"},"PeriodicalIF":2.2,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/06/br-57-4-256.PMC9812732.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9204825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid development of lower leg compartment syndrome following firearm injury in a patient with moderate hemophilia B. 中度血友病B患者火器损伤后下肢筋膜室综合征的快速发展。
IF 2.2 Q2 HEMATOLOGY Pub Date : 2022-12-31 DOI: 10.5045/br.2022.2022112
Jelena Bodrozic, Danijela Lekovic, Igor Koncar, Natasa Sulović Dzelatović, Predrag Miljic
REFERENCES 1. Graux C, Cools J, Melotte C, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004;36:1084-9. 2. Ragg S, Zehentner BK, Loken MR, Croop JM. Evidence for BCR/ABL1-positive T-cell acute lymphoblastic leukemia arising in an early lymphoid progenitor cell. Pediatr Blood Cancer 2019;66:e27829. 3. Govaerts I, Jacobs K, Vandepoel R, Cools J. JAK/STAT pathway mutations in T-ALL, including the STAT5B N642H mutation, are sensitive to JAK1/JAK3 inhibitors. Hemasphere 2019;3:e313. 4. Sharma P, Rana S, Sreedharanunni S, et al. An evaluation of a fluorescence in situ hybridization strategy using air-dried blood and bone-marrow smears in the risk stratification of pediatric B-lineage acute lymphoblastic leukemia in resource-limited settings. J Pediatr Hematol Oncol 2021;43:e481-5. 5. Graux C, Stevens-Kroef M, Lafage M, et al. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia 2009;23:125-33. 6. Deenik W, Beverloo HB, van der Poel-van de Luytgaarde SC, et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia 2009;23:627-9. 7. Li X, Ping N, Wang Y, et al. Case report: a case with Philadelphia chromosome positive T-cell lymphoblastic lymphoma and a review of literature. Front Oncol 2021;10:584149. 8. Jain P, Kantarjian H, Jabbour E, et al. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). Am J Hematol 2017;92:E3-4. 9. Ballerini P, Busson M, Fasola S, et al. NUP214-ABL1 amplification in t(5;14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance. Leukemia 2005; 19:468-70. 10. Barber KE, Martineau M, Harewood L, et al. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 2004;18:1153-6. 11. Kim HJ, Woo HY, Koo HH, Tak EY, Kim SH. ABL oncogene amplification with p16(INK4a) gene deletion in precursor T-cell acute lymphoblastic leukemia/lymphoma: report of the first case. Am J Hematol 2004;76:360-3. 12. Chen Y, Zhang L, Huang J, et al. Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and NUP214-ABL1 fusion: a case report. Exp Ther Med 2017;14:3979-84. 13. Peterson JF, Pitel BA, Smoley SA, et al. Detection of a cryptic NUP214/ABL1 gene fusion by mate-pair sequencing (MPseq) in a newly diagnosed case of pediatric T-lymphoblastic leukemia. Cold Spring Harb Mol Case Stud 2019;5:a003533. 14. De Keersmaecker K, Lahortiga I, Graux C, et al. Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia. Leukemia 2006;20:2202-4. 15. Bernasconi P, Calatroni S, Giardini I, et al. ABL1 amplification in T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet 2005;162:146-50.
{"title":"Rapid development of lower leg compartment syndrome following firearm injury in a patient with moderate hemophilia B.","authors":"Jelena Bodrozic,&nbsp;Danijela Lekovic,&nbsp;Igor Koncar,&nbsp;Natasa Sulović Dzelatović,&nbsp;Predrag Miljic","doi":"10.5045/br.2022.2022112","DOIUrl":"https://doi.org/10.5045/br.2022.2022112","url":null,"abstract":"REFERENCES 1. Graux C, Cools J, Melotte C, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004;36:1084-9. 2. Ragg S, Zehentner BK, Loken MR, Croop JM. Evidence for BCR/ABL1-positive T-cell acute lymphoblastic leukemia arising in an early lymphoid progenitor cell. Pediatr Blood Cancer 2019;66:e27829. 3. Govaerts I, Jacobs K, Vandepoel R, Cools J. JAK/STAT pathway mutations in T-ALL, including the STAT5B N642H mutation, are sensitive to JAK1/JAK3 inhibitors. Hemasphere 2019;3:e313. 4. Sharma P, Rana S, Sreedharanunni S, et al. An evaluation of a fluorescence in situ hybridization strategy using air-dried blood and bone-marrow smears in the risk stratification of pediatric B-lineage acute lymphoblastic leukemia in resource-limited settings. J Pediatr Hematol Oncol 2021;43:e481-5. 5. Graux C, Stevens-Kroef M, Lafage M, et al. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia 2009;23:125-33. 6. Deenik W, Beverloo HB, van der Poel-van de Luytgaarde SC, et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia 2009;23:627-9. 7. Li X, Ping N, Wang Y, et al. Case report: a case with Philadelphia chromosome positive T-cell lymphoblastic lymphoma and a review of literature. Front Oncol 2021;10:584149. 8. Jain P, Kantarjian H, Jabbour E, et al. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). Am J Hematol 2017;92:E3-4. 9. Ballerini P, Busson M, Fasola S, et al. NUP214-ABL1 amplification in t(5;14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance. Leukemia 2005; 19:468-70. 10. Barber KE, Martineau M, Harewood L, et al. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 2004;18:1153-6. 11. Kim HJ, Woo HY, Koo HH, Tak EY, Kim SH. ABL oncogene amplification with p16(INK4a) gene deletion in precursor T-cell acute lymphoblastic leukemia/lymphoma: report of the first case. Am J Hematol 2004;76:360-3. 12. Chen Y, Zhang L, Huang J, et al. Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and NUP214-ABL1 fusion: a case report. Exp Ther Med 2017;14:3979-84. 13. Peterson JF, Pitel BA, Smoley SA, et al. Detection of a cryptic NUP214/ABL1 gene fusion by mate-pair sequencing (MPseq) in a newly diagnosed case of pediatric T-lymphoblastic leukemia. Cold Spring Harb Mol Case Stud 2019;5:a003533. 14. De Keersmaecker K, Lahortiga I, Graux C, et al. Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia. Leukemia 2006;20:2202-4. 15. Bernasconi P, Calatroni S, Giardini I, et al. ABL1 amplification in T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet 2005;162:146-50.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"57 4","pages":"281-284"},"PeriodicalIF":2.2,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/3e/br-57-4-281.PMC9812729.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10634863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NK-cell trogocytosis of CD19 antigen: a rare B-ALL MRD mimicker. CD19抗原的nk细胞巨噬症:一种罕见的B-ALL MRD模拟物。
IF 2.2 Q2 HEMATOLOGY Pub Date : 2022-12-31 DOI: 10.5045/br.2022.2022235
Devasis Panda, Amardeep Pathak, Narender Tejwani, Anurag Mehta
{"title":"NK-cell trogocytosis of CD19 antigen: a rare B-ALL MRD mimicker.","authors":"Devasis Panda,&nbsp;Amardeep Pathak,&nbsp;Narender Tejwani,&nbsp;Anurag Mehta","doi":"10.5045/br.2022.2022235","DOIUrl":"https://doi.org/10.5045/br.2022.2022235","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"57 4","pages":"249"},"PeriodicalIF":2.2,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/f2/br-57-4-249.PMC9812724.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10643567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetic and genetic investigation of SOCS-1 gene in patients with multiple myeloma. 多发性骨髓瘤患者SOCS-1基因的表观遗传学及遗传学研究。
IF 2.2 Q2 HEMATOLOGY Pub Date : 2022-12-31 DOI: 10.5045/br.2022.2022097
Fatıma Ceren Tuncel, Istemi Serin, Sacide Pehlivan, Yasemin Oyaci, Mustafa Pehlivan

Background: The suppressor of cytokine signaling-1 (SOCS-1) functions to induce an appropriate immune response and is an essential physiological regulator of interferon signaling. DNA methylation involves adding a methyl group to the carbon 5 position of cytosine. Besides comparing SOCS-1 gene methylation status between patients with multiple myeloma (MM) and healthy controls, this study also aimed to demonstrate the effect of SOCS-1 gene distribution and the effect of methylation of SOCS-1 on progression-free survival (PFS) and overall survival (OS).

Methods: This study included 120 patients diagnosed with MM between January 2018 and 2020 and 80 healthy individuals. The distribution of the SOCS-1 genotypes was statistically compared between MM patients and healthy controls. Additionally, the statistically significant effects of these genotypes on survival were examined.

Results: The CA/CA genotype of SOCS-1 was significantly higher in healthy controls (P=0.001), while the Del/Del genotype was significantly higher in patients with MM (P=0.034). The percent methylated reference (PMR) value of the SOCS-1 gene was significantly higher in the healthy controls (median, 43.48; range, 2.76‒247.75; P=0.001). Patients with a PMR value of ≥43.48 were 3.125 times more likely to develop progression than those with a PMR value of <43.48.

Conclusion: The effects of SOCS-1 polymorphisms on the pathogenesis of.

背景:细胞因子信号传导抑制因子-1 (SOCS-1)的功能是诱导适当的免疫反应,是干扰素信号传导的重要生理调节因子。DNA甲基化包括在胞嘧啶的碳5位置添加一个甲基。除了比较多发性骨髓瘤(MM)患者和健康对照者的SOCS-1基因甲基化状态外,本研究还旨在证明SOCS-1基因分布和SOCS-1甲基化对无进展生存期(PFS)和总生存期(OS)的影响。方法:本研究纳入了2018年1月至2020年1月诊断为MM的120例患者和80例健康个体。对MM患者与健康对照者的SOCS-1基因型分布进行统计学比较。此外,这些基因型对生存率的影响具有统计学意义。结果:正常对照组中CA/CA基因型显著高于正常对照组(P=0.001), MM患者中Del/Del基因型显著高于正常对照组(P=0.034)。SOCS-1基因的甲基化参考值(PMR)在健康对照组中显著更高(中位数为43.48;范围2.76 - -247.75;P = 0.001)。PMR值≥43.48的患者发生进展的可能性是PMR值<43.48的患者的3.125倍。结论:SOCS-1基因多态性在肝癌发病机制中的作用。
{"title":"Epigenetic and genetic investigation of SOCS-1 gene in patients with multiple myeloma.","authors":"Fatıma Ceren Tuncel,&nbsp;Istemi Serin,&nbsp;Sacide Pehlivan,&nbsp;Yasemin Oyaci,&nbsp;Mustafa Pehlivan","doi":"10.5045/br.2022.2022097","DOIUrl":"https://doi.org/10.5045/br.2022.2022097","url":null,"abstract":"<p><strong>Background: </strong>The suppressor of cytokine signaling-1 (SOCS-1) functions to induce an appropriate immune response and is an essential physiological regulator of interferon signaling. DNA methylation involves adding a methyl group to the carbon 5 position of cytosine. Besides comparing SOCS-1 gene methylation status between patients with multiple myeloma (MM) and healthy controls, this study also aimed to demonstrate the effect of SOCS-1 gene distribution and the effect of methylation of SOCS-1 on progression-free survival (PFS) and overall survival (OS).</p><p><strong>Methods: </strong>This study included 120 patients diagnosed with MM between January 2018 and 2020 and 80 healthy individuals. The distribution of the SOCS-1 genotypes was statistically compared between MM patients and healthy controls. Additionally, the statistically significant effects of these genotypes on survival were examined.</p><p><strong>Results: </strong>The CA/CA genotype of SOCS-1 was significantly higher in healthy controls (<i>P</i>=0.001), while the Del/Del genotype was significantly higher in patients with MM (<i>P</i>=0.034). The percent methylated reference (PMR) value of the SOCS-1 gene was significantly higher in the healthy controls (median, 43.48; range, 2.76‒247.75; <i>P</i>=0.001). Patients with a PMR value of ≥43.48 were 3.125 times more likely to develop progression than those with a PMR value of <43.48.</p><p><strong>Conclusion: </strong>The effects of SOCS-1 polymorphisms on the pathogenesis of.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"57 4","pages":"250-255"},"PeriodicalIF":2.2,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/77/a0/br-57-4-250.PMC9812727.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10628163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Blood Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1